We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Imaging Mass Cytometry Uncovers Novel Breast Cancer Subgroups

By LabMedica International staff writers
Posted on 03 Feb 2020
Changing the course of how diseases are treated and ultimately cured requires a comprehensive understanding of complex cellular phenotypes and their interrelationships in the spatial context of the tissue microenvironment.

Single-cell analyses have revealed extensive heterogeneity between and within human tumors, but complex single-cell phenotypes and their spatial context are not at present reflected in the histological stratification that is the foundation of many clinical decisions.

Scientists at the University of Zurich (Zurich, Switzerland) and their colleagues used imaging mass cytometry to simultaneously quantify 35 biomarkers, resulting in 720 high-dimensional pathology images of tumor tissue from 352 patients with breast cancer, with long-term survival data available for 281 patients. More...
The team concentrated their efforts on single cells within these images to deeply profile tumors' phenotypes and organization.

The investigators used the Hyperion Imaging System (Fluidigm, South San Francisco, CA, USA) which combines immunohistochemical staining with mass-spectrometry-based detection to generate images. For their analysis, they designed a breast cancer-specific imaging mass cytometry panel of 35 antibodies, including ones aimed at detecting established targets like estrogen receptor, progesterone receptor, and HER2, but also the proliferation marker Ki-67 and cell lineage markers. The team reported that their images were comparable to those generated via immunohistochemistry or immunofluorescence approaches.

By quantifying the expression of these markers, the team could gauge the spatial features of these single cells and place them into phenotype clusters, of which they identified 14 main ones. Additionally, they uncovered 18 single-cell pathology subgroups. These subgroups, they noted, differed from the classical clinical subtypes and were associated with distinct clinical outcomes. For instance, single-cell pathology subgroup 1 (SCP1) was associated with patients with a promising prognosis, while SCP3 was linked to a poorer prognosis.

When they compared clinically defined subtypes and single-cell pathology subgroups, the scientists found the single-cell-based approach was better able to predict the overall survival of a patient. They replicated their analysis on a set of tumor samples from 73 patients and likewise uncovered the same cellular metaclusters and single-cell pathology subgroups. They noted, though, a difference in the proportion of the subgroups present, which they attributed to differences in the patient-selection strategies for the two cohorts.

Chris Linthwaite, MBA, president and CEO of Fluidigm, said, “This landmark study is the first to demonstrate the potential clinical value of highly multiplexed Imaging Mass Cytometry to identify breast cancer subtypes that correlate with clinical outcomes. By shedding new light with single-cell spatial images and data about the features of the tumor microenvironment, we believe this study will further increase adoption of IMC in translational and clinical investigatios to deliver better predictive and personalized approaches to cancer care in the future.” The study was published on January 20, 2020 in the journal Nature.

Related Links:
University of Zurich
Fluidigm



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.